| Japanese |
|---|
| Title | 99mTc-MIBIの臨床的有用性の評価 - 第III相多施設共同試験 - |
|---|
| Subtitle | ≪原著≫ |
|---|
| Authors | 鳥塚莞爾*, 久保敦司**, 西村恒彦***, 玉木長良**** |
|---|
| Authors(kana) | |
|---|
| Organization | *福井医科大学, **慶應義塾大学病院放射線科, ***国立循環器病センター放射線診療部, ****京都大学医学部放射線核医学科 |
|---|
| Journal | 核医学 |
|---|
| Volume | 28 |
|---|
| Number | 12 |
|---|
| Page | 1447-1462 |
|---|
| Year/Month | 1991/12 |
|---|
| Article | 原著 |
|---|
| Publisher | 日本核医学会 |
|---|
| Abstract | 「要旨」新しい心筋イメージング剤である99mTc-MIBIの臨床的有用性の評価を目的として, 各種心疾患患者464例を対象に第III相多施設共同試験を実施した. 本剤の心筋シンチグラムは, Planar像・SPECT像ともに201TlClより有意に鮮明であり, 心筋の血流状態をよく反映していると考えられた. 本剤の陽性率は, 心筋梗塞症例, 狭心症例ともに高く, 201TlClと比較し遜色はなかった. さらに, ファーストパス法の併用により, 心筋シンチグラフィと同時に心機能の評価も可能であると考えられた. 本剤投与直後より一過性の異常味覚が認められたが, その程度はいずれも軽度であり, 身体所見・臨床検査値においても, 一定の傾向をもった変動は認められず, 安全性の高い薬剤と考えられた. 以上, 安全性を含めて総合的に評価された臨床的有用性は全症例の93.1%に認められ, 本剤は99mTc-標識心筋血流イメージング製剤として有望と結論された. |
|---|
| Practice | 臨床医学：一般 |
|---|
| Keywords | 99mTc-MIBI, Myocardial perfusion, First-pass, 201TlCl. |
|---|
| English |
|---|
| Title | Clinical Evaluation of 99mTc-Hexakis 2-Methoxy Isobutyl Isonitrile (MIBI) : Multicenter Phase III Clinical Trial |
|---|
| Subtitle | - Original Articles - |
|---|
| Authors | Kanji TORIZUKA*, Atsushi KUBO**, Tsunehiko NISHIMURA***, Nagara TAMAKI**** |
|---|
| Authors(kana) | |
|---|
| Organization | *Fukui Medical School, **Department of Radiology, Keio University Hospital, ***Department of Radiology, National Cardiovascular Center, ****Department of Radiology and Nuclear Medicine, Kyoto University Faculty Medicine |
|---|
| Journal | The Japanese Journal of nuclear medicine |
|---|
| Volume | 28 |
|---|
| Number | 12 |
|---|
| Page | 1447-1462 |
|---|
| Year/Month | 1991/12 |
|---|
| Article | Original article |
|---|
| Publisher | THE JAPANESE SOCIETY OF NUCLEAR MEDICINE |
|---|
| Abstract | [Summary] Multicenter Phase III clinical trial on a new myocardial imaging agent, 99mTc-hexakis 2-methoxy isobutyl isonitrile (99mTc-MIBI), was carried out in 464 patients with various cardiac disorders. Both planar and tomographic images provided high-quality regional myocardial perfusion images which correlated well with 201TlCl images. The positive ratios of myocardial infarction and angina pectoris by the agent were as high as that of 201TlCl. In addition, ventricular function and wall motion could be assessed with first-pass and ECG gated studies. There was no serious adverse reaction which were attributed to 99mTc-MIBI in any of patients studied. A transient metallic taste was observed immediately after the injection in approximately 64% of the patients. Based on its safety and efficacy, the clinical usefulness of 99mTc-MIBI was observed in 562 (93.1%) of 604 injections. In conclusion, 99mTc-MIBI was useful as a imaging agent of myocardial blood flow. |
|---|
| Practice | Clinical medicine |
|---|
| Keywords | 99mTc-MIBI, Myocardial perfusion, First-pass, 201TlCl. |
|---|